- Home
- FMY vs RANI Comparison
FMY vs RANI Comparison
Compare FMY & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- RANI
- Stock Information
- Founded
- FMY 2005
- RANI 2012
- Country
- FMY United States
- RANI United States
- Employees
- FMY N/A
- RANI N/A
- Industry
- FMY Finance/Investors Services
- RANI Medicinal Chemicals and Botanical Products
- Sector
- FMY Finance
- RANI Health Care
- Exchange
- FMY Nasdaq
- RANI Nasdaq
- Market Cap
- FMY 51.1M
- RANI 55.3M
- IPO Year
- FMY N/A
- RANI 2021
- Fundamental
- Price
- FMY $12.19
- RANI $1.39
- Analyst Decision
- FMY
- RANI Strong Buy
- Analyst Count
- FMY 0
- RANI 6
- Target Price
- FMY N/A
- RANI $11.33
- AVG Volume (30 Days)
- FMY 10.1K
- RANI 145.1K
- Earning Date
- FMY 01-01-0001
- RANI 03-31-2025
- Dividend Yield
- FMY 6.98%
- RANI N/A
- EPS Growth
- FMY N/A
- RANI N/A
- EPS
- FMY N/A
- RANI N/A
- Revenue
- FMY N/A
- RANI $1,028,000.00
- Revenue This Year
- FMY N/A
- RANI N/A
- Revenue Next Year
- FMY N/A
- RANI N/A
- P/E Ratio
- FMY N/A
- RANI N/A
- Revenue Growth
- FMY N/A
- RANI N/A
- 52 Week Low
- FMY $10.71
- RANI $1.20
- 52 Week High
- FMY $12.17
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- FMY 55.97
- RANI 46.29
- Support Level
- FMY $12.12
- RANI $1.20
- Resistance Level
- FMY $12.22
- RANI $1.56
- Average True Range (ATR)
- FMY 0.07
- RANI 0.09
- MACD
- FMY 0.01
- RANI -0.02
- Stochastic Oscillator
- FMY 87.05
- RANI 52.78
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.